The company’s future will depend on the Phase III results from the trial, although that won’t get off the ground just yet. It also sidelined a program in hepatitis B to reserve cash. Its stock $FNCH has fallen 85% over the past year, from $14.04 to $2.10 at the closing bell Thursday. Although the company showed some of the first positive results in a randomized microbiome trial in 2020, it has come on hard times as the larger biotech market has taken a downturn.Įarlier this month, the company laid off 37 employees, or 20% of its workforce. The hold couldn’t come sooner for Finch. Finch now says those concerns have been resolved after “a review of information Finch provided related to its SARS-CoV-2 screening procedures and associated informed consent language.”

In March 2022, though, the company said the agency raised questions about those procedures and paused enrollment in a Phase III trial.

Beginning in early 2021, the company says it was able to start getting new donors again, first because its contract manufacturer employed SARS-CoV-2 screening methods and then because it bought out some of the manufacturer’s technology and employed the same screening methods. 1, 2019, but Finch said they were able to continue trials with samples banked before that date. In March 2020, the agency prohibited Finch from dosing trial patients with drug derived from any donor samples taken after Dec.

Finch for inbox pro